August 6, 2014 — Medical market research group Decision Resources finds that the United States clot management device market will expand through 2022, particularly in the later years. This will be primarily as a result of increasing uptake of neurovascular embolectomy devices, designed for treating stroke patients, as well as pharmacomechanical thrombectomy (PMT) devices to manage venous thromboembolism (VTE). Overall, U.S. clot management device revenues will reach approximately $700 million by 2022.
Other key findings from Decision Resources Group's coverage of the U.S. clot management device market:
Neurovascular embolectomy devices: The introduction of stent retrievers in the United States in 2012 caused a dramatic jump in the market for neurovascular embolectomy devices. Clinical evidence showed that these devices are able to achieve a far superior rate of vessel recanalization compared to previous generations of devices. Furthermore, growth in the number of primary stroke centers in the United States, which are increasingly likely to offer endovascular treatment options, will drive neurovascular embolectomy device uptake.
Clinical evidence: There is still, however, demand for clinical evidence to prove that endovascular devices lead to better outcomes in stroke patients. As a result, a number of trials are ongoing in this area, including THERAPY, SWIFT PRIME and POSITIVE.
PMT device adoption to treat VTE: VTE, which includes deep vein thrombosis (DVT) or pulmonary embolism, often requires treatment with thrombolytic agents in addition to mechanical disruption of the clot itself. PMT devices were developed for this purpose and are experiencing adoption at the expense of other clot management devices that use only lytic therapy or mechanical action in isolation.
"There are, however, some factors that will continue to limit the U.S. clot management device market. For example, anticoagulation therapy remains the standard treatment for DVT, and the Food and Drug Administration has recently approved novel oral anticoagulants for use in this indication. Nevertheless, the ongoing ATTRACT trial is expected to support clot management device intervention to treat DVT, which should ultimately boost procedure volumes," said Decision Resources Group Senior Analyst Sean Messenger.
He said the inferior vena cava filter (IVCF) market declined from 2012 to 2013. “These devices saw rampant uptake in the U.S. in the last decade and were often placed as a prophylactic measure,” Messenger said. “However, recent studies have shown that complication rates were higher than expected, and some patients have even taken legal action. Nonetheless, product developments in this space, such as the Angel Catheter from BiO2, could lead to returning demand for IVCFs in the future."
Messenger has written a Medtech 360 report on this subject entitled U.S. Markets for Clot Management Devices 2014. Decision Resources Group's Marketrack provides market share data by brand for the interventional cardiology and peripheral vascular device markets.
For more information: www.DecisionResourcesGroup.com
July 27, 2021 
